3VG.F 0.98 (-19.01%)
FR0013286259BiotechnologyBiotechnology

Theranexus (3VG.F) Stock Highlights

0.98 | -19.01%
2024-04-23 04:06:25
Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The companys therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinsons disease, THN201 for the treatment of neurocognitive disorders in Alzheimers disease and THN101 for neuropathic pain.

Statistics

Range Today
0.98 0.98
Volume Today 0
Range 1 Year
0.58 2.3
Volume 1 Year 17.23K
Range 3 Year
0.58 14.04
Volume 3 Year 25.89K
Range 10 Year
0.58 21.5
Volume 10 Year 29.19K

Highlights

Market Capitalization 9.29M (micro)
Floating Shares 6.45M
Current Price 0.98
Price To Earnings -0.93
Price To Revenue 33.05
Price To Book 2.19
Earnings Per Share -1.16
Payout Ratio 0%

Performance

Latest -19.01%
1 Month -2%
3 Months 0%
6 Months -7.55%
1 Year -26.32%
3 Years -93.02%
5 Years -93.49%
10 Years -93.49%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.